… DOAC)‐treated patients about safety and efficacy in extremes of body weight. The aims
of this systematic review were to investigate the association of body weight and patient‐important …

… on the safety and efficacy of these new drugs in patients with extreme body weights, and …
evaluate the effect of extreme body weight (BW) on safety and efficacy of DOACs using data …

… decrease of 4.0 kg in body weight in the group participating in … each decrease of 1 kg in body
weight there was a decrease of … body weight was stable or body weight was still declining. If …

… The efficacy of antiplatelet drugs may differ in specific patient subgroups. We aimed to assess
the efficacy and safety … to diabetes status, age, gender, body mass index, and body weight. …

… for effective and safe anti-obesity agents that can produce and maintain weight loss and …
trials to assess the efficacy and safety of the newly approved anti-obesity agent rimonabant. …

… body weight, a prespecified analysis of efficacy (at least 75% improvement from baseline
in PASI score [PASI 75] at week 28) by 10-kg increments was presented for data pooled from …

… body weight from baseline to the end of the study (weeks 12–13) in all beloranib treatment
groups (Figure 1). The reduction in body weight … in mean and percent body weight was dose-…

… However, the efficacy and safety of apixaban in patients with body weight ≥ 120 kg and …
efficacy, safety, and exposure of apixaban for the treatment of VTE in patients with a body weight …

… ) with known baseline body weight at randomization were … to body weight: 1985 (10.9%)
patients were in the low-weight group (≤60 kg), 15 172 (83.6%) were in the midrange weight …

… of phentermine/topiramate ER for 1 year had a total body weight loss of 7.8% and 9.8%,
respectively, as compared to the weight loss of 1.2% in patients administered with placebo. Thus…